Health Care

Insider buying spurs optimism for Zymeworks’ oncology pipeline; executive purchases signal confidence amid 70% YTD gain, regulatory alignment, and rising investor sentiment.

CG Oncology insider trades reveal Mulay James’ buy‑low/sell‑high strategy and large option stake, signaling confidence while managing liquidity and future upside.

Bruker Nano’s insider trades reveal a strategic buy‑low and sell‑high pattern, signaling potential undervaluation amid its TOFWERK acquisition and future growth.

Discover how Zymeworks’ insider trades signal a strategic shift—executive equity tied to milestones may boost long‑term growth and investor value.

Forte Biosciences insider buying shows executive confidence amid a 38 % weekly stock surge, AI‑driven oncology R&D, and value‑based payer strategies.

Insider buy at Clene Inc. shows confidence in its CNM‑Au8 biomarker; a $6.50 unit purchase, including warrants, could surge if FDA approval succeeds.

Insider buying at DENTSPLY SIRONA shows leadership confidence amid volatility—discover why executives keep buying shares and what it could mean for the company’s future.

Twist Bioscience CFO sells shares to cover RSUs – does the 9% weekly rally signal a pullback? Explore insider trends, DNA platform strength, and investor outlook.

Insmed CEO’s insider trades reveal a disciplined 10‑b‑5‑1 strategy—buying low, selling high—to fund rare‑disease R&D, boost liquidity, and signal confidence for investors and payers alike.

Explore how EDAP TMS SA’s CFO and key executives hold and vest large share blocks, revealing confidence in HIFU growth and future valuation prospects.